|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
From the Department of Biochemistry, College of
Medicine, University of Vermont, Burlington.
Several platelet inhibitors were examined in a tissue factor
(TF)-initiated model of whole blood coagulation. In vitro coagulation of human blood from normal donors was initiated by 25 pM TF while contact pathway coagulation was suppressed using corn trypsin inhibitor. Products of the reaction were analyzed by immunoassay. Preactivation of platelets with the thrombin receptor activation peptide did not influence significantly the clotting time or
thrombin-antithrombin III complex (TAT) formation. Addition of
prostaglandin E1 (5 µM) caused a significant delay in
clotting (10.0 minutes) versus control (4.3 minutes). The prolonged
clotting time is correlated with delays in platelet activation,
formation of TAT, and fibrinopeptide A (FPA) release. In blood from
subjects receiving acetylsalicylic acid (ASA or aspirin), none of the
measured products of coagulation were significantly affected.
Similarly, no significant effect was observed when 5 µM dipyridamole
(Persantine) was added to the blood. Antagonists of the platelet
integrin receptor glycoprotein (gp) IIb/IIIa had intermediate effects
on the reaction. A 1- to 2-minute delay in clot time and FPA formation
was observed with addition of the antibodies 7E3 and Reopro (abciximab)
(10 µg/mL), accompanied by a 40% to 70% reduction in the maximal
rate of TAT formation and delay in platelet activation. The
cyclic heptapetide, Integrilin (eptifibatide), at 5 µM
concentration slightly prolonged clot time and significantly attenuated
the maximum rate of TAT formation. The disruption of the
gpIIb/IIIa-ligand interaction not only affects platelet aggregation,
but also decreases the rate of TF-initiated thrombin generation in
whole blood, demonstrating a potent antithrombotic effect
superimposed on the antiaggregation characteristics.
(Blood. 2001;97:2314-2322) The importance of the platelet in normal hemostasis
and in disease states, such as atherosclerosis and thrombosis, is
well established.1-5 A particularly germane example is the
platelet-rich thrombus, which forms on fissured or ruptured
atherosclerotic plaques.3-5 Although the slow formation of
the underlying plaques is a progressive disease that serves to narrow
the lumen of the vessel over an extended period of time, it is the
sudden and catastrophic superposition of the platelet-rich thrombotic
occlusion on these lesions that is central to nearly all ischemic
coronary events. General acceptance that the ultimate occlusive event
is thrombotic in nature has led to the development of strategies that
attempt to ameliorate, inhibit, or reverse this final phase of
the coronary disease process. Some of the newest strategies focus on
inhibition of platelet functions, which contribute to the formation of
the thrombotic occlusion.
The generation of thrombin during the blood clotting process can be
divided into 2 semidiscrete intervals, the initiation and propagation
phases.6 During the initiation phase nanomolar amounts of
thrombin and picomolar amounts of other coagulation enzymes are
generated. Clot occurs at the inception of the propagation phase, which
is characterized by rapid and near quantitative thrombin generation. By
this point activation of platelets and cleavage of factor V and factor
VIII are almost complete.7 In normal blood, the thrombin
activation process is independent of platelet or factor V activation,
but is limited by the generation of factor Xa.6,7
Normal platelet function has been divided into 3 processes: adhesion,
aggregation, and activation (including surface phospholipid rearrangements and secretory pathways8-11). These
functions bestow on the platelet its antihemorrhagic qualities and are
regulated by a variety of mechanisms.12 The most potent
platelet agonist is The multifaceted roles of the platelet in hemostasis provide targets
for the development of strategies to arrest the occlusive phase of
atherosclerotic disease. A number of inhibitors have been described,
which are directed at different aspects of platelet function.
Prostaglandin E1 (PGE1) is a potent antagonist
of platelet activation and functions through the platelet prostaglandin
receptor by up-regulating adenylate cyclase production of intracellular cyclic adenosine monophosphate (cAMP).12 The weaker
platelet inhibitor aspirin (acetylsalicylic acid or ASA) has been found to be mildly effective at reducing the risk of coronary events or their
recurrence.24,25 This effect is presumably due to aspirin's role as irreversible inhibitor of the cyclooxygenase activity of prostaglandin H synthase in the arachidonic acid pathway leading to thromboxane A2 (TXA2) synthesis for
release on platelet activation.26,27 Inhibitors of the
platelet integrin glycoprotein (gp) IIb/IIIa have been designed, which
interfere with the ability of these receptors to bind fibrin(ogen), and
thus to form the large platelet-fibrin aggregates, which serve as the
foundation of the thrombus.28 Recently, the murine
monoclonal antibody 7E3 (and the humanized variant, known as c7E3,
Reopro, or abciximab) has proven clinically effective as an adjuvant in
the management of high-risk patients undergoing percutaneous
transluminal coronary angioplasty (PTCA).29-31 Similarly,
a cyclic heptapeptide containing a "KGD" sequence has also been
developed as a high-affinity mimic of the fibrinogen "RGD"
sequence, which binds to the gpIIb/IIIa receptor (Integrilin, or
eptifibatide). This peptidomimetic has proven effective as an adjuvant
in PTCA and in treatment of unstable angina.32,33 Although
the above agents or their analogs exhibit significant clinical benefits
in treating acute coronary syndromes, it is unclear whether their
therapeutic properties are localized to the platelet aggregation
function alone or extend to thrombin generation within the thrombotic
occlusion. The goal of this study was to examine the relationships
between therapeutic doses of these reagents and TF-induced
coagulation in whole minimally altered human blood. This was
accomplished using a laboratory model we have developed, which directly
examines various aspects of the coagulation reaction in freshly drawn
human blood.7,34
Materials
Human donors
Preparation of TF/lipid reagent Tissue factor (5 nM) was relipidated into small unilammelar vesicles37 of 25% PS/75%PC (PCPS) (10 µM total lipid) in HBS plus calcium (2 mM) for 30 minutes at 37°C. Concentrated sucrose (60% w/v) was subsequently added to the relipidation mixture to 10% final to stabilize the vesicles for long-term freezer storage (up to 12 months). Aliquots of the reagent (200 µL) were lyophilized and stored at 20°C, which could be rehydrated 60 minutes before each experiment and used with reproducible results.
PT and aPTT assays Assays were performed in plastic tubes (VWR Scientific, West Chester, PA, no. 60818-270) on 100-µL samples of fresh frozen, citrated human plasma using the manual "tilt-tube" approach described by the manufacturer of the PT or aPTT reagent. When testing the effect of buffer or inhibitor, no more than 10 µL of the additive was mixed with 90 µL plasma, to minimize dilution errors.Coagulation in whole blood The protocol used is a modification of Rand and colleagues,7 performed at the Clinical Research Center, Fletcher Allen Health Care (Burlington, VT). For all platelet agents except the aspirin study (see below), studies of clotting in freshly drawn, nonanticoagulated whole blood were performed simultaneously in 2 series (16/series) of capped, polystyrene tubes modified to accept reagents as described.7 One series contained buffer only (control series), the other contained an appropriate amount of the antiplatelet agent under investigation (experimental series). To suppress contact activation, CTI was added to all tubes (10 µL, 5 mg/mL stock); in addition, the first tube of each series of 16 tubes was designated the zero tube and was preloaded with 1 mL 50 mM EDTA in HBS, pH 7.4, and 10 µL 10 mM FPRck (diluted in 0.01 M HCl). As a control for possible TF in the blood resulting from the draw or other sources, all but the last tube in each series (designated "TF")
were preloaded with relipidated TF.
For studies using platelet agents other than ASA, the platelet agent under investigation was preloaded into the experimental series from a stock prepared at a concentration appropriate to give the desired final concentration in the blood (typically 100- to 400-fold). Care was taken to avoid premixing of the reagents prior to initiation. An equivalent volume of solvent/vehicle (HBS, pH 7.4, or 95% ethanol for the PGE1 or DMSO for dipyridamole studies) was preloaded into each tube of the corresponding control series. Following venipuncture under the protocol approved by the Human Studies Committee at the University of Vermont,7 the initial 2 mL blood was discarded, samples were drawn for blood analyses (complete blood count, PT, aPTT, blood chemistry, etc), and about 40 mL fresh whole human blood was drawn into a repeating pipette or fitted with a plastic barrel syringe (Eppendorf Combi-Tip, Eppendorf, Westbury, NY). Another 1 to 2 mL blood was discarded, and the reaction was initiated by rapid distribution of the remainder (1 mL/tube) to each of the 16 preloaded tubes in each series (control and experimental). The final concentrations of additives in the various experiments are as follows: CTI (50 µg/mL), relipidated TF (3.1 pM, 25 pM, and 200 pM), and, where appropriate, the platelet agonist or antagonist (PGE1, TRAP, dipyridamole, and Integrilin 5 µM; 7E3 and Reopro 10 µg/mL). For each of the ASA (aspirin) experiments, a similar procedure was used as described above; however, only one series of 16 tubes was prepared as above with no additions other than CTI and TF. Each of the control studies was performed using normal donor whole blood (~20 mL) drawn prior to administration of ASA; each of the experimental studies was performed on a separate day on blood from the same donor treated according to the ASA regimen described above (see "Human donors"). For each series in all experiments, periodic quenching of each tube
(except the zero tube) was carried out at predefined intervals after
initiation using EDTA and FPRck as described above (see discussion of
zero tubes). Quenched samples were obtained for each series tracing the
reaction progress up to 20 to 30 minutes after initiation. The samples
were centrifuged to remove cellular components and clots, and an
aliquot (200 µL) of the resulting serum from each tube was filtered
to remove cellular contaminants for osteonectin assays (0.2 µm
Acrodisc, Gelman Sciences, Ann Arbor, MI). From the remaining serum,
both reducing (1% Immunoassays Commercial ELISAs for FPA, TAT, and platelet -granule release
(osteonectin) were performed according to manufacturers' protocols, with corrections for sample dilution by added quench solution (1.00 mL). Results were analyzed on a Vmax microtiter plate reader (Molecular
Devices, Menlo Park, CA) equipped with SOFTMax version 2.0 software and
an IBM Personal System 2 Model 30/286 PC. In each assay, a minimum of 5 standard concentrations were run in duplicate, with duplicate sample
determinations at each time point. The relationship between
concentration of standard and optical density was established by
fitting the data to either a 4-parameter or log-logit fit, as described
by the manufacturer (Molecular Devices). For each of the analytes (TAT,
FPA, and osteonectin), duplicate data describing each time point for a
given donor were averaged over all experiments.
Assay conditions developed by Rand and colleagues7 allow studies of coagulation directly in whole human blood in vitro under conditions that attempt to model the physiologic coagulation reaction in vivo. A tripartite approach is central to this model, using minimally modified whole blood initiated with limiting (pM) concentrations of relipidated TF (PCPS/TF ratio 2000:1) and CTI to suppress the contact pathway, which does not play a significant role in the normal hemostatic reaction.13-16 Such conditions permit examination of the reaction with clotting at times similar to those observed with in vivo assays like the template bleeding time. The conditions also produce a reaction that is sensitive to factor VIII, factor IX, and factor XI deficiencies known to be associated with hemophilias A, B, and C, and therefore provide a model of hemostasis that is improved over traditional plasma assays such as the PT and aPTT.38 Finally, use of whole human blood as the substrate for the reaction affords direct examination of hemostatic mechanisms on the platelet and cellular surfaces relevant to the reaction in vivo; this aspect is particularly important in allowing study of the effects of pharmaceutical agents (such as antiplatelet drugs) on the coagulation reaction in a safe ex vivo model. At present, the whole blood model provides simultaneous measurements of clot formation, thrombin generation (via TAT), fibrin formation (via FPA), and platelet activation (via osteonectin release), among others.7 Of particular value have been the determinations of thrombin level over the course of the reaction, which show that thrombin generation proceeds in 3 distinct phases. From initiation of the reaction until the clot is observed, thrombin is produced at very low rates (< 1 nM/min). These low rates of thrombin generation have been ascribed to the limiting concentrations of prothrombinase produced during this initiation phase6 of the reaction, limited by the small amounts of factor Xa being produced. However, at clot time significant platelet and cofactor activation are observed, indicating that the low levels of thrombin generated are sufficient to potentiate the system for an increase in the rate of thrombin generation. This postclot time thrombin generation, propagation phase, is largely driven by factor Xa derived from the intrinsic Xase during this phase. The rate of thrombin generation during the propagation phase routinely exceeds 50 to 100 nM/min. Clotting occurs coincident with the inception of the propagation phase.7,34 Finally, rates of thrombin generation are observed to slow as a result of endogenous regulatory mechanisms in what is referred to as the termination phase of the reaction. Analyses performed across these phases of the reaction provide a means of characterizing the effects of external influences (such as antiplatelet agents) on the reaction as a whole. Platelet activation and suppression prior to TF: TRAP and PGE1 Under normal conditions, the TF-initiated reaction in whole blood does not appear to be platelet activation limited.39 In keeping with this conclusion the current study found the reaction not to be significantly accelerated by the platelet agonist, TRAP sequence SFLLRN.40 The reaction initiated by 25 pM TF was studied in normal blood in the absence ( , Figure
1) and presence ( ) of TRAP (Table
1), which fully activated the platelets
within 1 minute of initiation as illustrated by osteonectin release
(Figure 1B). In the absence of the TRAP, clotting occurred at 3.1 minutes (arrow a) and was accelerated slightly by addition of agonist (2.3 minutes, arrow b). However, this observed shortening of the clot
time is most likely attributable to increased platelet aggregation leading to an early "call" of the clot formation, because the clotting time is estimated visually and is the most subjective parameter among the evaluated in this model of blood coagulation. This
is supported by TAT profiles collected in the absence and presence of
activation peptide, which show no significant alteration in thrombin
generation (Figure 1A). Thus, TRAP had little effect on the thrombin
generation profile, despite significant prior platelet activation.
Together with earlier results, demonstrating significant generation of
the factor Va and platelet activation prior to clot
time,7,34 these data reinforce the conclusion that in the
TF-initiated reaction in normal blood (and presumably during
physiologic coagulation as well) platelet and factor V activation are
not the limiting factors of TF-induced thrombin generation during the
initiation phase. Rather, factor Xa appears to be the limiting
component of the thrombin-generating prothrombinase complex.6
Like prostaglandin I2, PGE1 is a natural
prostanoid, which inhibits intracellular release of stored
Ca++ and platelet activation by up-regulation of adenylate
cyclase to form cAMP. The clinical usefulness of this reagent is
limited by its short half-life in the circulation and an ability to
stimulate peripheral vasodilation; however, some preliminary studies
have been described with analogs of this reagent for use in controlling pulmonary hypertension.41,42 Figure
2 describes results with PGE1
(5 µM) added in vitro to whole blood initiated to clot by 25 pM TF.
Inhibition of the TF pathway of blood coagulation is observed. The
clotting times in the control experiment and in the presence of
PGE1 are indicated in each panel of the figure (arrows a
and b, respectively). In the presence of PGE1, clot time is
prolonged from 4.4 minutes to 9.3 minutes. Thrombin generation, shown
as TAT formation over the course of the experiment (Figure 2A), is
severely affected by this agent. In the absence of PGE1, thrombin generation is very slow during the initiation phase (
Release profiles of FPA for the control and in the presence of
PGE1 are compared in Figure 2B. The normal profile ( The effect of PGE1 on platelet activation is evident in the
platelet osteonectin and PF4 release profiles (Figure 2C and D, respectively). The normal profile of osteonectin release ( In summary, the results suggest that PGE1 at this concentration inhibits the TF-initiated reaction in whole blood in vitro by suppressing formation of the membrane sites required for complex enzyme assembly. Thus, thrombin generation during both the initiation and propagation phases becomes platelet activation dependent and is reduced by PGE1. The results obtained using PGE1 in this model system resemble those obtained in whole blood from thrombocytopenic patients with platelet counts less than 11 000/µL.39 Aspirin (ASA) and dipyridamole (Persantine) No inhibitory effects on the TF pathway of blood coagulation were discerned in 2 of 3 individuals ingesting aspirin (Table 1). In fact, clotting time in whole blood initiated by 25 pM TF appeared on average to be slightly shorter in the presence of the drug than in control experiment (3.8 and 4.1 minutes, respectively); however, the degree of variability in these experiments precludes conclusions concerning any aspirin accelerating effect. For individual "1" aspirin administration decreased clotting time by 0.5 minute, whereas for individual "3" this decrease reached 1.5 minutes (Figure 3). Similarly, thrombin generation (Figure 3A) and fibrin conversion (Figure 3B) profiles for these 2 individuals were shifted to the left in the presence of the drug ()
in comparison with the corresponding cases in the absence of ASA (),
whereas osteonectin release was not significantly influenced by aspirin
administration (Figure 3C). For individual "2" the clotting time
was prolonged by 1 minute after aspirin administration (3.1 and 4.1 minutes, respectively). The maximum rates of TAT generation, FPA
formation, and osteonectin release appeared on average to be slightly
slower than normal (Table 1); however, the variability in these assays
does not allow any conclusion concerning deceleration of these
processes by ASA.
These studies failed to find a significant role for aspirin at the dose used in attenuating TF-initiated coagulation and underscore the complexity of the physiologic aspirin effect. The data suggest that aspirin's therapeutic effect does not arise primarily from direct modulation of platelet procoagulant function in the TF pathway to thrombin generation because aspirin does not appear to have any measurable effect on platelet activation in this system. This may be due to 2 factors. First, platelet activation in this model system is thrombin mediated as underscored by the observation that addition of nanomolar quantities of hirudin completely inhibit platelet activation. Second, thrombin, a potent platelet agonist, overrides the weak inhibitory effects of aspirin via the TXA2 pathway. Dipyridamole (Persantine) is a pyrimidopyrimidine derivative that inhibits platelet aggregation, but the mechanism of action of this compound has been controversial.43 It has been established that plasma concentrations of this derivative are 2 to 6 µM after oral administration of pharmaceutical doses. An in vitro addition of 5 µM dipyridamole to whole blood only marginally affected the clotting time, increasing it by 0.1 to 0.3 minute versus control (Table 1). Neither thrombin generation, FPA formation, nor osteonectin release was significantly altered by the presence of this platelet antagonist. Inhibitors of gpIIb/IIIa Inhibitors of the gpIIb/IIIa complex on the platelet surface are designed to block the interactions between fibrinogen and platelets, inhibiting the formation of platelet aggregates.28 We examined the effect of the murine antibody 7E3, the chimeric human/murine antibody Reopro (abciximab) and cyclic heptapetide Integrilin (eptifibatide) on blood coagulation induced by 200 pM, 25 pM, and 3.1 pM TF.In studies of whole blood with TF concentration of 200 pM, the clotting
time was 1.25 minutes (Figure 4; arrows
a-c). At this initiator concentration no significant effects of
gpIIb/IIIa antagonists on the blood coagulation process were observed.
Clotting times and maximum rates of TAT formation were similar in the
control experiment (
At a TF concentration of 25 pM both forms of antibody (7E3, Figure
5; and Reopro, Table 1) at 10 µg/mL
modestly delayed clot formation (Figure 5, arrow b). On average, 7E3
prolonged the clotting time from 4 to 5.1 minutes and Reopro from 4.2 to 6.3 minutes (Table 1). This reflects a modest reduction in thrombin
generation versus normal in the presence of the inhibitors during the
initiation phase of the reaction. With Integrilin (Figure
6), clot formation was delayed slightly
(by 0.6 minute; arrow b) versus control (arrow a). Consistent with this
observation, the initiation phase of thrombin generation (3.9 minutes)
was slightly prolonged by this inhibitor (to 4.5 minutes).
Thrombin generation during the propagation phase was
significantly suppressed by all 3 gpIIb/IIIa inhibitors. With 7E3
(Figure 5A, Both inhibitory antibodies produced delays in FPA release (Figure 5B;
7E3; Platelet osteonectin (Figure 5C for 7E3) and PF4 release (Figure 5D)
are delayed versus normal ( In summary, the antibody inhibitors of the gpIIb/IIIa complex influence thrombin generation, fibrin formation, and platelet activation in both the initiation and propagation phases of the reaction in whole blood induced by 25 pM TF. The largest effect appears to be on the propagation phase of the reaction. Integrilin also has a pronounced effect on the propagation phase, with a more limited effect on the initiation phase of thrombin generation. Experiments were also performed at a lower (3.1 pM) TF concentration. Under these conditions both agents (Integrilin and Reopro) prolonged the clotting time from 8.2 to 14.3 minutes (Integrilin) and almost 20 minutes (Reopro) and depressed the maximum levels of TAT formed (data not shown).
Studies from this laboratory and others7,34,44-46 using physiologically relevant systems to model the TF pathway have demonstrated that thrombin generation is not uniform over time but occurs in distinct phases. During an initiation phase, low rates of thrombin generation (< 1 nM/min) are observed as a result of low rates of factor Xa produced primarily by the factor VIIa-TF complex.6,7,34,44-46 Subsequently, enhanced levels of factor Xa are made available by participation of the factor IXa-factor VIIIa complex,38 and a burst of thrombin generation (> 50 nM/min) occurs during a propagation phase of the reaction. Clot formation, the usual end-point of in vitro assays, occurs approximately at the transition between the initiation and propagation phases and coincides with the onset of the thrombin burst.7,34 By this point in the reaction in whole blood, activation of platelets and cleavage of factor V and factor VIII are significant.7 In normal blood, the limiting component in the ultimate activation of prothrombin to thrombin is not platelet or factor V activation, but factor Xa generation.6,7 Thus, as anticipated, preactivation of platelets with TRAP has little effect on thrombin generation. In contrast, the potent platelet inhibitor PGE1 significantly prolongs the initiation phase of thrombin generation, which is reflected in a doubling of the clotting time and delays in the FPA release and thrombin generation. PGE1 also delays platelet degranulation (osteonectin release), with accompanying reduction in the presentation of platelet surface receptors for procoagulant enzyme complex formation thus impairing coagulation complex assembly.10,11 This impaired complex assembly in the presence of PGE1 is reflected by a decreased thrombin generation rate during the propagation phase to less than half that observed normally. Ultimately, platelet activation and fibrin formation, though delayed, proceed to completion despite the reduced prothrombin activation rates. Thus, although thrombin levels are sufficient to fully activate platelets and cleave fibrinogen at maximal rates during the propagation phase, suppression of platelet activation by the potent antagonist PGE1 imparts a substantial platelet activation dependency to the process of thrombin generation. Aspirin (ASA) at clinically relevant doses did not alter clotting time, thrombin generation, fibrin formation, or platelet activation in blood induced to clot by addition of TF. This result is similar to that noted by Kjalke and associates who reported no effect of aspirin administration on the thrombin generation in a reconstituted system in the presence of platelets when the reaction was initiated by TF.47 Thus, at the doses used, aspirin does not overcome the thrombin activation of the platelets, the agonist principally responsible for platelet activation in the TF-initiated reaction. Similarly, the addition of dipyridamole (Persantine) to whole blood in vitro at pharmacologic concentration43 has no effect on the processes occurring during TF-induced blood coagulation in this model. The inhibitors of the platelet gpIIb/IIIa receptor exhibit somewhat different behaviors in influencing the TF-initiated reaction. In reactions initiated by 25 pM TF, antibodies 7E3 (the murine form) and Reopro abciximab or c7E3 (the chimeric murine/human form) each provide a modest prolongation of the initiation phase evidenced by slight delays in clotting time and delays in both FPA and platelet osteonectin release profiles. However, both 7E3 and Reopro significantly reduce thrombin generation during the propagation phase of the reaction. Despite reduced thrombin generation the ultimate maximum rates of FPA formation and osteonectin release were observed. Both the fibrin and platelet reactions reached completion. These observations of reduced thrombin generation in the presence of anti-gpIIb/IIIa antibodies are consistent with those described in a defibrinated plasma model.48 The cyclic heptapeptide Integrilin (eptifibatide) slightly delayed thrombin generation at 25 pM TF during the initiation phase, resulting in a slightly prolonged clotting time. However, at pharmacologic concentration the influence of Integrilin was less than that observed for the 7E3 and Reopro antibodies. Integrilin, similarly to antibody inhibitors, reduced the rate of thrombin generation during the propagation phase of the reaction. At higher TF concentrations (200 pM), neither Reopro nor Integrelin at pharmacologic concentrations affected clot formation, clotting times, or the thrombin generation profiles. At the lower initiator concentration (3.1 pM TF) the efficiencies of both gpIIb/IIIa inhibitors is enhanced. Under these conditions, both Integrilin and Reopro significantly prolonged the clotting time. These significant prolongations of clotting time may explain the bleeding observed with these agents.49-51 Overall, the gpIIb/IIIa inhibitors appear to significantly influence either the quantitative or qualitative expressions of the procoagulant complexes leading to thrombin.
We thank Sara G. Paradis and Joshua D. Dee for the technical assistance. We thank Dr Shu Len Liu and Dr Roger Lundblad for providing us with TF; Dr Joseph A. Jakubowski for providing 7E3; Dr Uma Sinha for providing Reopro and Integrilin; Dr Paula Tracy for providing TRAP; and Dr Richard Jenny for providing osteonectin ELISA kits and FPRck.
Submitted April 20, 2000; accepted December 12, 2000.
Supported in part by RR00109, P01 HL 46703 (K.G.M.), PHS T32 HL07594-12 (K.G.M.) from the National Institutes of Health, and by a TALENT stipend of the Netherlands Organization of Scientific Research (C.v.V.).
Portions of this work were presented at the 39th Annual Meeting of the American Society of Hematology, December 5-9, 1997, San Diego, CA (Blood 90 [suppl 1]:29a, abstract 114).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Kenneth G. Mann, Department of Biochemistry, College of Medicine, University of Vermont, Burlington, VT 05405-0068; e-mail: kmann{at}zoo.uvm.edu.
1. Weiss HJ. Antiplatelet therapy: properties of platelets. N Eng J Med. 1978;298:1344-1347[Medline] [Order article via Infotrieve]. 2. Ware AJ, Coller BS. Platelet morphology, biochemistry and function. In: Beutler E,Lichtman MA,Coller BS,Kipps TJ, eds. Williams Hematology. 5th ed. New York, NY: McGraw-Hill; 1995:1161-1176. 3. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med. 1992;326:242-250[Medline] [Order article via Infotrieve]. 4. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med. 1992;326:310-318[Medline] [Order article via Infotrieve]. 5. Badimon L, Badimon JJ, Fuster V. Pathogenesis of thrombosis. In: Verstraete M,Fuster V,Topol EJ, eds. Cardiovascular Thrombosis: Thrombocardiology and Thromboneurology. 2nd ed. Philadelphia, PA: Lippincott-Raven; 1998:23-44.
6.
Butenas S, van 't Veer C, Mann KG.
Evaluation of the initiation phase of blood coagulation using ultrasensitive assays for serine proteases.
J Biol Chem.
1997;272:21527-21533
7.
Rand MD, Lock JB, van 't Veer C, Gaffney DP, Mann KG.
Blood clotting in minimally altered whole blood.
Blood.
1996;88:3432-3445 8. Hartwig JH. Platelet morphology. In: Loscalzo J,Schaefer AI, eds. Thrombosis and Hemorrhage. 2nd ed. Baltimore, MD: Williams & Wilkins; 1998:207-228. 9. Bevers EM, Comfinius P, Van Rijn JLML, Hemker HC, Zwaal RFA. Generation of prothrombin converting activity and the exposure of phosphatidylserine at the outer surface of platelets. Eur J Biochem. 1982;122:429-436[Medline] [Order article via Infotrieve]. 10. Schroit AJ, Zwaal RFA. Transbilayer movement of phospholipids in red cell and platelet membranes. Biochim Biophys Acta. 1991;1071:313-329[Medline] [Order article via Infotrieve].
11.
Zwaal RFA, Schroit AJ.
Pathophysiologic implications of membrane phospholipid asymmetry in blood cells.
Blood.
1997;89:1121-1132 12. Kroll NM, Sullivan R. Mechanisms of platelet activation. In: Loscalzo J,Schafer AI, eds. Thrombosis and Hemorrhage. 2nd ed. Baltimore, MD: Williams & Wilkins; 1998:261-291. 13. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance and regulation. Biochemistry. 1991;30:10363-10370[CrossRef][Medline] [Order article via Infotrieve]. 14. Rapaport SI, Rao LVM. The tissue factor pathway: how it has become a `prima ballerina.' Thromb Haemost. 1995;74:7-17[Medline] [Order article via Infotrieve]. 15. Mann KG, Krishnaswamy S, Lawson JH. Surface-dependent hemostasis. Semin Hematol. 1992;29:213-226[Medline] [Order article via Infotrieve]. 16. Jenny NS, Mann KG. Coagulation cascade: an overview. In: Loscalzo J,Schafer AI, eds. Thrombosis and Hemorrhage. 2nd ed. Baltimore, MD: Williams & Wilkins; 1998:3-27.
17.
Pieters J, Lindhout T, Hemker HC.
In situ-generated thrombin is the only enzyme that effectively activates factor VIII and factor V in thromboplastin-activated plasma.
Blood.
1989;74:1021-1024
18.
Blomback B.
Fibrinogen and fibrin 19. Doolittle RF. Fibrinogen and fibrin. Annu Rev Biochem. 1984;53:195-229[Medline] [Order article via Infotrieve]. 20. Sixma JJ, van den Berg A. The haemostatic plug in haemophilia A: a morphological study of haemostatic plug formation in bleeding time skin wounds of patients with severe haemophilia A. Br J Haematol. 1985;58:741-753.
21.
Bevilacqua MP, Pober JS, Majeau GR.
Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular cells.
J Exp Med.
1984;160:618-623
22.
Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone MA Jr.
Recombinant tumor necrosis factor induces procoagulant activity in cultured human endothelium: characterization and comparison with the actions of interleukin 1.
Proc Natl Acad Sci U S A.
1986;83:4533-4537 23. Bevilacqua MP, Gimbrone MA Jr. Inducible endothelial functions in inflammation and coagulation. Semin Thromb Hemost. 1987;13:425-433[Medline] [Order article via Infotrieve].
24.
Patrono C.
Aspirin as an antiplatelet drug.
N Engl J Med.
1994;330:1287-1294 25. Vane JR. Inhibition of prostaglandins as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231:232-235[Medline] [Order article via Infotrieve]. 26. Thomgreen M, Shafi S, Bom GVR. Thromboxane A2 in skin-bleeding-time blood and in clotted venous blood before and after administration of acetylsalicylic acid. Lancet. 1983;1:1075-1078[Medline] [Order article via Infotrieve]. 27. Patrono C, Ciabattoni G, Pinca E, et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res. 1980;17:317-327[CrossRef][Medline] [Order article via Infotrieve]. 28. Coller BS, Peerschke EL, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest. 1983;72:325-328.
29.
The EPIC Investigators.
Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty: the EPIC investigation.
N Engl J Med.
1994;330:956-961
30.
The EPILOG Investigators.
Platelet glycoprotein IIb/lIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
N Engl J Med.
1997;336:1689-1699 31. The CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention on refractory unstable angina: the CAPTURE study. Lancet. 1997;349:1429-1435[CrossRef][Medline] [Order article via Infotrieve].
32.
Schulman SP, Goldschmidt-Clennont PJ, Topol EJ, et al.
Effects of Integrilin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina: a multicenter trial.
Circulation.
1996;94:2083-2089 33. The IMPACT-II Investigators. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet. 1997;349:1422-1428[CrossRef][Medline] [Order article via Infotrieve].
34.
Cawthern KM, van 't Veer C, Lock JB, DiLorenzo ME, Branda RF, Mann KG.
Blood coagulation in hemophilia A and hemophilia C.
Blood.
1998;91:4581-4592 35. Kettner C, Shaw E. D-Phe-Pro-ArgCH2Cl-A selective affinity label for thrombin. Thromb Res. 1979;14:969-973[CrossRef][Medline] [Order article via Infotrieve]. 36. Hojima Y, Pierce JV, Pisano J. Hageman factor fragment inhibitor in corn seeds: purification and characterization. Thromb Res. 1980;20:149-162[CrossRef][Medline] [Order article via Infotrieve]. 37. Barenholz Y, Gibbes D, Litman BJ, Goll J, Thompson TE, Carlson FD. A simple method for the preparation of homogeneous phospholipid vesicles. Biochemistry. 1977;16:2806-2810[CrossRef][Medline] [Order article via Infotrieve].
38.
Osterud B, Rapaport SI.
Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation.
Proc Natl Acad Sci U S A.
1977;74:5260-5264 39. Cawthern KM, Pennucci JJ, Mann KG, Branda RF. The effect of thrombocytopenia on the tissue factor pathway [abstract]. Blood. 1998;92 (suppl 1):36a. 40. Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1991;64:1057-1068[CrossRef][Medline] [Order article via Infotrieve]. 41. FitzGerald GA, Patrono C. Antiplatelet drugs. In: Verstraete M,Fuster V,Topol EJ, eds. Cardiovascular Thrombosis: Thrombocardiology and Thromboneurology. 2nd ed. Philadelphia, PA: Lippincott-Raven; 1998:121-139. 42. Okano Y, Yoshioka T, Shimouchi A, Satoh T, Kuneida T. Orally active prostacyclin analogue in primary pulmonary hypertension. Lancet. 1997;349:1365[CrossRef][Medline] [Order article via Infotrieve]. 43. FitzGerald GA. Dipyridamole. N Engl J Med. 1987;316:1247-1257[Medline] [Order article via Infotrieve].
44.
Lawson JH, Kalafatis M, Stram S, Mann KG.
A model for the tissue factor pathway to thrombin; I: an empirical study.
J Biol Chem.
1994;269:23357-23366
45.
van 't Veer C, Mann KG.
Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor-II.
J Biol Chem.
1997;272:4367-4377
46.
Jones KC, Mann KG.
A model for the tissue factor pathway to thrombin, II: a mathematical simulation.
J Biol Chem.
1994;269:23367-23373 47. Kjalke M, Oliver JA, Monroe DM, et al. The effect of active site-inhibited factor VIIa on tissue factor-initiated coagulation using platelets before and after aspirin administration. Thromb Haemost. 1997;78:1202-1208[Medline] [Order article via Infotrieve]. 48. Reverter JC, Beguin S, Kessels H, Kumar R, Hemker HC, Coller BS. Inhibition of platelet mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody: potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis." J Clin Invest. 1996;98:863-874[Medline] [Order article via Infotrieve]. 49. Winkley JM, Adams HP Jr. Potential role of abciximab in ischemic cerebrovascular disease. Am J Cardiol. 2000;85:47C-51C[CrossRef][Medline] [Order article via Infotrieve]. 50. Ali A, Patil S, Grady KJ, Schreiber TL. Diffuse alveolar hemorrhage following administration of tirofiban or abciximab: a nemesis of platelet glycoprotein Iib/IIIa inhibitors. Catheter Cardiovasc Interv. 2000;49:181-184[CrossRef][Medline] [Order article via Infotrieve]. 51. Vahdat B, Canavy I, Fourcade L, et al. Fatal cerebral hemorrhage and severe thrombocytopenia during abciximab treatment. Catheter Cardiovasc Interv. 2000;49:177-180[CrossRef][Medline] [Order article via Infotrieve].
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  P. A. Gurbel, R. C. Becker, K. G. Mann, S. R. Steinhubl, and A. D. Michelson Platelet Function Monitoring in Patients With Coronary Artery Disease J. Am. Coll. Cardiol., November 6, 2007; 50(19): 1822 - 1834. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Schneider and B. E. Sobel Conundrums in the Combined Use of Anticoagulants and Antiplatelet Drugs Circulation, July 17, 2007; 116(3): 305 - 315. [Full Text] [PDF]
|
|
|
|
 |
|
 V. G. Nielsen, P. Audu, L. Cankovic, R. T. Lyerly III, B. L. Steenwyk, V. Armstead, and G. Powell Qualitative Thrombelastographic Detection of Tissue Factor in Human Plasma Anesth. Analg., January 1, 2007; 104(1): 59 - 64. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. C.A. Munnix, A. Strehl, M. J.E. Kuijpers, J. M. Auger, P. E.J. van der Meijden, M. A.M. van Zandvoort, M. G.A. oude Egbrink, B. Nieswandt, and J. W.M. Heemskerk The Glycoprotein VI-Phospholipase C{gamma}2 Signaling Pathway Controls Thrombus Formation Induced by Collagen and Tissue Factor In Vitro and In Vivo Arterioscler Thromb Vasc Biol, December 1, 2005; 25(12): 2673 - 2678. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Altman, A. Scazziota, S. Santoro, and C. Gonzalez Abciximab Does Not Inhibit the Increase of Thrombin Generation Produced in Platelet-Rich Plasma In Vitro by Sodium Arachidonate or Tissue Factor Clinical and Applied Thrombosis/Hemostasis, July 1, 2005; 11(3): 271 - 277. [Abstract] [PDF]
|
|
|
|
 |
|
 C. Leon, M. Alex, A. Klocke, E. Morgenstern, C. Moosbauer, A. Eckly, M. Spannagl, C. Gachet, and B. Engelmann Platelet ADP receptors contribute to the initiation of intravascular coagulation Blood, January 15, 2004; 103(2): 594 - 600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Leon, C. Ravanat, M. Freund, J.-P. Cazenave, and C. Gachet Differential Involvement of the P2Y1 and P2Y12 Receptors in Platelet Procoagulant Activity Arterioscler Thromb Vasc Biol, October 1, 2003; 23(10): 1941 - 1947. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. G. Mann Thrombin Formation Chest, September 1, 2003; 124 (2009): 4S - 10S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. G. Mann, S. Butenas, and K. Brummel The Dynamics of Thrombin Formation Arterioscler Thromb Vasc Biol, January 1, 2003; 23(1): 17 - 25. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Monroe, M. Hoffman, and H. R. Roberts Platelets and Thrombin Generation Arterioscler Thromb Vasc Biol, September 1, 2002; 22(9): 1381 - 1389. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. E. Brummel, S. G. Paradis, R. F. Branda, and K. G. Mann Oral Anticoagulation Thresholds Circulation, November 6, 2001; 104(19): 2311 - 2317. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Undas, K. Brummel, J. Musial, K. G. Mann, and A. Szczeklik Blood coagulation at the site of microvascular injury: effects of low-dose aspirin Blood, October 15, 2001; 98(8): 2423 - 2431. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
no ASA for > 1 month before experiment) then again after 3 days of 325 mg ASA twice a day (experimental series).
-mercaptoethanol) and nonreducing sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) samples were
prepared (60 µL serum, 190 µL 2% SDS-PAGE sample solution, heated
exactly 5 minutes at 98°C), then stored at 
) and
presence (
).
